Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial (original) (raw)

“…1) [16-18, 21-23, 33, 34]. Of these, 4 RCTs (1,694 patients) [21][22][23]33] were conducted in the neoadjuvant setting and 4 RCTs (3,820 patients) [16][17][18]34] were conducted in the adjuvant setting. Selected arms of neoadjuvant trials and their characteristics are listed in Table 1.…”

Section: Selected Trialsmentioning

See 2 more Smart Citations

“…1) [16-18, 21-23, 33, 34]. Of these, 4 RCTs (1,694 patients) [21][22][23]33] were conducted in the neoadjuvant setting and 4 RCTs (3,820 patients) [16][17][18]34] were conducted in the adjuvant setting. Selected arms of neoadjuvant trials and their characteristics are listed in Table 1.…”

Section: Selected Trialsmentioning

“…Three RCTs (2,132 patients) [17,18,34] included an arm with luminal disease subtype, 3 RCTs (618 patients) [17,18,34] included an arm with HER2-positive disease, and 4 RCTs (1,070 patients) [16][17][18]34] included an arm with TNBC.…”

Section: Selected Trialsmentioning

See 1 more Smart Citation

“…Accumulating evidence shows that the presence of an immune response in breast cancers correlates with estrogen receptor negative (ER-) subtypes (i.e. the HER2 and basal-like intrinsic subtypes) among whom there is an association with favorable outcomes 1–3 . In contrast, the more common ER+ breast cancer subtypes rarely display such heightened immune responses, which when present are associated with unfavorable prognosis 4-6 .…”

Section: Introductionmentioning

“…7 Moreover, the presence of an adaptive type 1 immune response within the tumor microenvironment is an independent predictor of survival in breast cancer. [8][9][10][11] Collectively, these data paint a more complicated picture of the tumor than a mass of heterogeneous malignant clones. The emerging view is that the development of effective treatments for cancer will require us to consider the cancer as a dynamic system, in which malignant cells interact with a variety of other cell types present within the tumor microenvironment to maintain a disease state.…”

Section: Introductionmentioning